Used in targeted cancer therapy, particularly for solid tumors expressing CEACAM6 such as colorectal, pancreatic, and lung cancers. Binds selectively to CEACAM6, enabling tumor detection and delivery of cytotoxic agents. Investigated for use in immunoimaging and antibody-drug conjugates (ADCs) to improve treatment specificity. Also supports cancer cell depletion in combination with immune effector mechanisms like ADCC and CDC. Currently in preclinical and early clinical development for oncology applications.